{
    "nctId": "NCT05371860",
    "briefTitle": "Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response",
    "officialTitle": "Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer, HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Feasibility of enrolling patients measured by proportion of recruited patients to participate in the trial",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female\n* Age \u2265 40 years\n* Patients must have a tissue diagnosis of HER2+ breast cancer\n* Patients must have documented clinical T1-3, N0, M0 disease prior to receiving neo-adjuvant chemotherapy\n* Patients must have undergone neo-adjuvant chemotherapy and targeted HER2 therapy prior to surgery and plan for completion of adjuvant systemic therapy as directed by their medical oncologist\n* Patients must have completed partial mastectomy/lumpectomy and sentinel node biopsy or axillary node dissection.\n* Patient must have documented pathologic complete response (defined as no residual invasive or in situ disease in the breast or axilla, including free of isolated tumor cells or micrometastasis)\n\nExclusion Criteria:\n\n* Breastfeeding\n* Prior history of breast cancer (invasive or ductal carcinoma in-situ) in either breast\n* Prior adjuvant radiation therapy\n* Patients with diagnosis of inflammatory breast cancer\n* Patients with known BRCA mutation or other known breast cancer related deleterious mutations",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}